- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05546853
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (LAP-NET1)
March 7, 2024 updated by: University Hospital, Grenoble
The study will assess the safety of the association of NP137 with the standard of care mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association with mFOLFIRINOX to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is a multicentric, prospective, single arm phase 1b trial.
This study will enroll 43 to 52 patients and consists of 2 parts: Safety Lead-in Phase and Expansion Phase.
Initially, 3 to 12 patients will be enrolled into a Safety Lead-in Phase based on a 3 + 3 design, with the possibility of dose de-escalation, to confirm the recommended dose of NP137.The Expansion Phase will start after completion of Safety Lead-in Phase at the confirmed dose and will include 40 patients.
Patients will be assigned to the experimental arm (NP137 + mFOLFIRINOX).
Study Type
Interventional
Enrollment (Estimated)
52
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anna BOROWIK
- Phone Number: 0476769314
- Email: aborowik@chu-grenoble.fr
Study Contact Backup
- Name: Laure Bordy
- Phone Number: 0476766150
- Email: LBordy@chu-grenoble.fr
Study Locations
-
-
-
Bordeaux, France, 33404
- Recruiting
- CHU de Bordeaux
-
Contact:
- Jean Fredéric BLANC
-
Lille, France, 59037
- Recruiting
- CHRU Lille
-
Contact:
- Anthony TURPIN
-
Lyon, France, 69008
- Recruiting
- Hopital Prive Jean Mermoz
-
Contact:
- Pascal ARTRU
-
Paris, France, 75013
- Recruiting
- AP-HP Pitié Salpetrière
-
Contact:
- Jean-Baptiste BACHET
-
Poitiers, France, 86000
- Recruiting
- CHU Poitiers
-
Contact:
- Camille EVRARD
-
Reims, France, 51092
- Recruiting
- CHU de Reims
-
Contact:
- Olivier BOUCHE
-
Rennes, France, 35033
- Recruiting
- CHU Rennes
-
Contact:
- Astrid LIEVRE
-
Saint-Étienne, France, 42055
- Recruiting
- CHU St Etienne
-
Contact:
- Nicolas WILLIET
-
-
Alpes
-
Grenoble, Alpes, France, 38043
- Recruiting
- CHU de Grenoble Alpes
-
Contact:
- Gaël ROTH
- Phone Number: Groth@chu-grenoble.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age from 18 to 79 years
- Able to understand and sign informed consent
- Histologically or cytologically proven diagnosis of pancreatic ductal adenocarcinoma
- Locally advanced pancreatic cancer considered unresectable according to NCCN Guidelines® Version 2.2021
- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors RECIST 1.1 criteria
- Male, or non-pregnant and non-lactating female
- Women patients of childbearing potential* must have a negative serum/urine pregnancy test at screening and baseline, and be willing to use a highly effective** contraception. The patient should be advised to continue the contraception for at least 6 months following the completion of dosing. Women with cessation for > 24 months of previously occurring menses, or women of any age who have had a hysterectomy, or have had both ovaries removed will be considered to be of non-childbearing potential
- Male patients of reproductive potential must be willing to use one acceptable method of contraception, as judged by Investigator and Sponsor and/or to refrain from donating sperm from the time of screening through at least 6 months following the completion of dose administration
- No prior systemic therapy, radiation therapy, or resection for pancreatic cancer
- Life expectancy ≥ 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate liver function:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN),
- Bilirubin ≤ 1.5 x ULN or in subjects with biliary stenting ≤ 2.0 x ULN
- Alkaline phosphatase < 2.5 x ULN
- Subjects with biliary stenting do not need to wait for their alkaline phosphatase to become < 2.5 x ULN if their total bilirubin, AST and ALT have improved to within required study levels with criteria 12a and 12b
- Adequate bone marrow function: platelets >100,000 cells/mm3, hemoglobin > 9.0 g/dl and absolute neutrophil count (ANC) >1,500 cells/mm3
- Adequate renal function: creatinine < 1.5 x ULN, creatinine clearance ≥ 30 mL/min/m2
- Adequate nutritional state with Albumin ≥ 2.5 g/dL
- Less than grade 2 pre-existing peripheral neuropathy (per CTCAE)
- Patients covered by Health Insurance System
Exclusion Criteria:
- Patients with resectable pancreatic cancer
- Evidence of the presence of metastases.
- Patients who have received prior systemic therapy, radiation therapy, or resection for pancreatic cancer or prior therapy with NP137
- Patients with known Dihydropyrimidine dehydrogenase (DPD) deficiency, or homozygosity for UGT1A1*28 polymorphism (UGT1A1 genotype analysis is not required to be eligible)
- Previous (within the past 3 years) or concurrent malignancy diagnosis except non-melanoma skin cancer and in situ carcinomas (excluding in situ breast cancer)
- History of severe (grade ≥ 3) allergic reactions to one of the components of chemotherapy, or NP137
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, may decrease subject's compliance to study's procedures or may render the patient at high risk from treatment complications in the opinion of the treating investigator
- Subjects with known poorly controlled comorbid conditions, including; congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), uncontrolled diabetes mellitus (DM) or neurologic disorders (not acutely related to pancreatic cancer) or limited function
- Major surgery within 4 weeks prior to signing informed consent form. Biliary stents are permitted
- History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
- History of allergy or hypersensitivity to any of the chemotherapy agents belonging to mFOLFIRINOX regimen
- Subjects with a history of chronic HCV, HBV or HIV infection
- Subjects who have been administered a live vaccine within four weeks prior to the first administration of therapy
- Subjects who cannot stop chronic medications that inhibit or induce CYP2C8 or CYP3A4
- Persons referred to in Articles L1121-5 to L1121-8 of the French code of public health (this corresponds to all persons protected: pregnant or parturient women, breastfeeding mothers, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure)
- Patients who have active infection requiring systemic therapy (other than HCV, HBV, HIV).
- Patients who participate or plan to participate in another interventional clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
NP137+ mFOLFIRINOX
|
NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
Calcium levofolinate will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 100 mg/m²
5 FU will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 2400 mg/m2 as a continuous intravenous infusion over 46 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Proportion of patients experiencing adverse events
Time Frame: At 6 months
|
Percentage Proportion of patients experiencing adverse events (AEs) of any grade and grade 3/4 AEs as defined by the National Cancer Institute - Common Terminology Criteria for Adverse Events (CTCAE v 5.0) at 6 months.
|
At 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall objective response rate (ORR)
Time Frame: At 2,4 and 6 months
|
Best overall objective response rate (ORR) according to RECIST 1.1
|
At 2,4 and 6 months
|
Overall survival (OS)
Time Frame: at 12 and 36 months
|
Median Overall survival (OS) and 12 months-OS rates.
OS is defined as the time between inclusion and death (all causes).
Patients alive will be censored at the date of last news.
|
at 12 and 36 months
|
Progression-Free Survival (PFS)
Time Frame: at 12 and 36 months
|
Median Progression-Free Survival (PFS) and 12 months-PFS rates.
PFS is defined as the time between inclusion and progression according to RECIST 1.1 or death (all causes).
Patients alive without progression will be censored at the date of last news.
|
at 12 and 36 months
|
Median Duration of response
Time Frame: at 36 months
|
Median Duration of response is defined as the time between first dose of treatment and progression according to RECIST 1.1.
Patients alive without progression will be censored at the date of last news.
|
at 36 months
|
Quality of life (QoL)
Time Frame: at 36 months
|
Quality of life will be studied by using the EORTC QLQ-C30 questionnaire (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire for Cancer).
A 5-point decrease of QLQ-C30 score will be considered as the minimal clinically significant deterioration of QoL.
|
at 36 months
|
time to deterioration
Time Frame: at 36 months
|
TTD will be defined as the time from inclusion in the study to deterioration of EORTC QLQ-C30 score with a decrease ≥5 points at any time point after the baseline score.
|
at 36 months
|
PK-PD evaluation
Time Frame: at 36 months
|
PK-PD evaluation: based on available PopPK modelisation and PK samples collected at the time of the response evaluation in this study
|
at 36 months
|
proportion of patients reaching surgery
Time Frame: at 36 months
|
Percentage surgical resection with R0/R1 margins
|
at 36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Gaël ROTH, MD PHD, University Hospital, Grenoble
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2023
Primary Completion (Estimated)
November 28, 2024
Study Completion (Estimated)
November 28, 2025
Study Registration Dates
First Submitted
September 15, 2022
First Submitted That Met QC Criteria
September 15, 2022
First Posted (Actual)
September 21, 2022
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Calcium-Regulating Hormones and Agents
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Oxaliplatin
- Leucovorin
- Irinotecan
- Calcium
- Levoleucovorin
Other Study ID Numbers
- 38RC22.0211
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
Clinical Trials on NP137
-
Centre Leon BerardNETRIS PharmaCompletedAdvanced Solid Tumor | Endometrial Carcinoma | Hormone Receptor PositiveFrance
-
Nabeel BadriNETRIS PharmaNot yet recruitingPancreatic CancerUnited States
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Centre Leon BerardNETRIS PharmaRecruitingAcute Myeloid Leukemia RefractoryFrance
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedOsteoporosis | Differentiated Thyroid CancerChina
-
NETRIS PharmaCentre Leon Berard; Merck Sharp & Dohme LLCRecruitingEndometrial Carcinoma | Cervix CarcinomaFrance
-
University Hospital, GrenobleNETRIS PharmaRecruiting